Cargando…
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
A potential drug-drug interaction exists between divalent and trivalent cations (Ca(2+), Fe(3+), Mg(2+), Al(3+), Zn(2+)) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledg...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452960/ https://www.ncbi.nlm.nih.gov/pubmed/32623580 http://dx.doi.org/10.1007/s40121-020-00307-4 |
_version_ | 1783575266252029952 |
---|---|
author | Rock, Alex E. DeMarais, Patricia L. Vergara-Rodriguez, Pamala T. Max, Blake E. |
author_facet | Rock, Alex E. DeMarais, Patricia L. Vergara-Rodriguez, Pamala T. Max, Blake E. |
author_sort | Rock, Alex E. |
collection | PubMed |
description | A potential drug-drug interaction exists between divalent and trivalent cations (Ca(2+), Fe(3+), Mg(2+), Al(3+), Zn(2+)) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements. This case represents a potential significant drug interaction between a commonly prescribed antiretroviral drug class and readily available over-the-counter divalent cation products. |
format | Online Article Text |
id | pubmed-7452960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-74529602020-09-03 HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir Rock, Alex E. DeMarais, Patricia L. Vergara-Rodriguez, Pamala T. Max, Blake E. Infect Dis Ther Case Report A potential drug-drug interaction exists between divalent and trivalent cations (Ca(2+), Fe(3+), Mg(2+), Al(3+), Zn(2+)) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements. This case represents a potential significant drug interaction between a commonly prescribed antiretroviral drug class and readily available over-the-counter divalent cation products. Springer Healthcare 2020-07-04 2020-09 /pmc/articles/PMC7452960/ /pubmed/32623580 http://dx.doi.org/10.1007/s40121-020-00307-4 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Rock, Alex E. DeMarais, Patricia L. Vergara-Rodriguez, Pamala T. Max, Blake E. HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir |
title | HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir |
title_full | HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir |
title_fullStr | HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir |
title_full_unstemmed | HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir |
title_short | HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir |
title_sort | hiv-1 virologic rebound due to coadministration of divalent cations and bictegravir |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452960/ https://www.ncbi.nlm.nih.gov/pubmed/32623580 http://dx.doi.org/10.1007/s40121-020-00307-4 |
work_keys_str_mv | AT rockalexe hiv1virologicreboundduetocoadministrationofdivalentcationsandbictegravir AT demaraispatricial hiv1virologicreboundduetocoadministrationofdivalentcationsandbictegravir AT vergararodriguezpamalat hiv1virologicreboundduetocoadministrationofdivalentcationsandbictegravir AT maxblakee hiv1virologicreboundduetocoadministrationofdivalentcationsandbictegravir |